Amphastar Pharmaceuticals (AMPH) Matches Q3 Earnings Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of 0.00% and 1.37%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock? Amphastar Pharmaceuticals (AMPH) came ou.....»»
Recap: Amphastar Pharmaceuticals Q1 Earnings
Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 58.82% over the past year to $0.27, which beat the estimate of $0.18. read more.....»»
Recap: Amphastar Pharmaceuticals Q4 Earnings
Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 128.57% year over year to $0.16, which beat the estimate of $0.14. read more.....»»
Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q3 2019 Results - Earnings Call Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q3 2019 Results - Earnings Call Transcript.....»»
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2019 Results - Earnings Call Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2019 Results - Earnings Call Transcript.....»»
Amphastar Pharmaceuticals (AMPH) Q4 2018 Earnings Conference Call Transcript
AMPH earnings call for the period ending December 31, 2018......»»
Amphastar Pharmaceuticals, Inc."s (AMPH) Management on Q4 2018 Results - Earnings Call Transcript
Amphastar Pharmaceuticals, Inc."s (AMPH) Management on Q4 2018 Results - Earnings Call Transcript.....»»
Amphastar Pharmaceuticals" (AMPH) Q1 2018 Results - Earnings Call Transcript
Amphastar Pharmaceuticals" (AMPH) Q1 2018 Results - Earnings Call Transcript.....»»
Amphastar Pharmaceuticals (AMPH) Shares Cross Above 200 DMA
Market News Video.....»»
Vertex Pharma stock rises on earnings, outlook beat
Vertex Pharmaceuticals Inc. shares rose in the extended session Thursday after the biotech drug maker's results and forecast topped Wall Street estimates. Vertex shares rose 2.9% after .....»»
Here is What Hedge Funds Think About Amphastar Pharmaceuticals Inc (AMPH)
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual i.....»»
Amphastar Pharmaceuticals (AMPH) Presents At Piper Jaffray Healthcare Conference - Slideshow
Amphastar Pharmaceuticals (AMPH) Presents At Piper Jaffray Healthcare Conference - Slideshow.....»»
RSI Alert: Amphastar Pharmaceuticals (AMPH) Now Oversold
Dividend Channel.....»»
Amphastar Pharmaceuticals Inc (AMPH) CEO & Chief Scientific Officer Jack Y. Zhang Sold $6. ...
Related Stocks: AMPH,.....»»
GW Pharma Analysts Raise Estimates After CBD Drug Epidiolex Shows Strong Uptake
GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) reported second-quarter earnings and revenue Tuesday that blew past estimates, sending .....»»
Schlumberger (SLB) Matches Q2 Earnings Estimates
Schlumberger (SLB) delivered earnings and revenue surprises of 0.00% and 1.90%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock? Want the latest recommendations from Za.....»»
Hancock Whitney (HWC) Matches Q2 Earnings Estimates
Hancock Whitney (HWC) delivered earnings and revenue surprises of 0.00% and 1.73%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock? Want the latest recommendations from Zacks Inv.....»»
Amphastar Pharmaceuticals (AMPH) Presents At Jefferies 2019 Healthcare Conference - Slideshow
Amphastar Pharmaceuticals (AMPH) Presents At Jefferies 2019 Healthcare Conference - Slideshow.....»»
Kala Pharmaceuticals (KALA) Reports Q1 Loss, Tops Revenue Estimates
Kala Pharma (KALA) delivered earnings and revenue surprises of 17.28% and 43.78%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock? Want the latest.....»»
Vanda Pharmaceuticals (VNDA) Q1 Earnings Top Estimates
Vanda (VNDA) delivered earnings and revenue surprises of 500.00% and -7.05%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock? Want the latest recommendations from Zacks Inv.....»»